Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

Explore this paper's citation graph

Summary

MK-3475 demonstrated activity in all major subgroups irrespective of ECOG PS, LDH levels, BRAFmutation, M stage, and number and type of prior therapy and may be an appropriate treatment for all pts with MEL.

Type
article
Published
2014-06-20
Cited by
143
References
0

Keywords

Medicine, Internal medicine, Cohort, Ipilimumab, Gastroenterology

References

No references recorded for this paper.

Cited by

Related papers